Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Geraldine M, Ferron"'
Autor:
Jean-Louis Pinquier, Frank A. S. Erwich, Sandrine Turpault, Franck Poitiers, Christine Roy, Linda E. Klumpers, Geraldine M. Ferron, Johan G. C. van Hasselt, Lineke Zuurman, Joop M. A. van Gerven
Publikováno v:
British Journal of Clinical Pharmacology. 76:65-77
Aim Cannabinoid receptor type 1 (CB1) antagonists have been developed for the treatment of obesity and associated risk factors. Surinabant is a high affinity CB1 antagonist in vitro. The aim of this study was to assess the magnitude of inhibition by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::209530f614adfebaa5fac4eeca02fd43
https://doi.org/10.1111/bcp.12071
https://doi.org/10.1111/bcp.12071
Publikováno v:
British Journal of Clinical Pharmacology. 56:39-45
Aims To evaluate potential pharmacokinetic interactions between phenobarbitone and retigabine, a new antiepileptic drug. Methods Fifteen healthy men received 200 mg of retigabine on day 1. On days 4–32, phenobarbitone 90 mg was administered at 22.0
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::004ebc7692edb7c6b4884b6cfc62f17a
https://doi.org/10.1046/j.1365-2125.2003.01825.x
https://doi.org/10.1046/j.1365-2125.2003.01825.x
Autor:
Geraldine M. Ferron, JoAnn Scatina, Simon E. Ball, Qian Xiang, Lilian G. Yengi, John Kao, C. Roland Wolf, Richard Fruncillo, Jinmei Pan
Publikováno v:
Analytical Biochemistry. 316:103-110
There is considerable interindividual variation in man’s ability to metabolize drugs and foreign compounds. These differences can partly be attributed to genetic polymorphisms that result in the generation of multiple phenotypes with different drug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f38a9f02b81783ff4673b928c854fc4
https://doi.org/10.1016/s0003-2697(03)00042-3
https://doi.org/10.1016/s0003-2697(03)00042-3
Autor:
Jeffrey Paul, Norbert G. Knebel, Katharina Erb, Lyette S Richards, Hans‐Peter Cnota, Robert Hermann, Geraldine M. Ferron, Peter Ruus, Steven M. Troy
Publikováno v:
Clinical Pharmacology & Therapeutics. 73:61-70
Background The novel antiepileptic drug retigabine is the first selective M-current potassium channel opener for KCNQ2/3 and KCNQ3/5 channels. Retigabine undergoes phase II metabolism (N-glucuronidation, acetylation) exclusively and renal excretion.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85f7e9c08dbe3bef91828792b989d4e7
https://doi.org/10.1067/mcp.2003.12
https://doi.org/10.1067/mcp.2003.12
Autor:
Geraldine M. Ferron, Jeffrey Paul, Paul J. Pockros, Richard A. Preston, Marybeth Turner, John Getsy, Robert J. Noveck, Madelyn Abell, Philip R. Mayer
Publikováno v:
Clinical Therapeutics. 23:1180-1192
Background: Patients with impaired hepatic function usually require gastric acid—suppressant therapy but are at increased risk for drug interactions and may require dosage adjustments. The proton pump inhibitor pantoprazole is rapidly absorbed and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25baabe3933fbb311d797870c3f76402
https://doi.org/10.1016/s0149-2918(01)80100-4
https://doi.org/10.1016/s0149-2918(01)80100-4
Publikováno v:
The Journal of Clinical Pharmacology. 41:149-156
The relationship between the pharmacokinetics of pantoprazole, an irreversible proton pump inhibitor, and its effect on gastric acid secretion was evaluated in humans and rats. Pantoprazole pharmacokinetics were studied in 6 rats (5 mg/kg, i.v.) and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67dbcaf25d2a8b82db32f015c22820ad
https://doi.org/10.1177/00912700122009953
https://doi.org/10.1177/00912700122009953
Publikováno v:
The Journal of Clinical Pharmacology. 39:1155-1161
The bioavailability of an oral nonaqueous solution of sirolimus was compared under fasting conditions and after a high-fat meal in a randomized, two-way crossover pharmacokinetic study. Healthy volunteers were administered a 15 mg single dose of siro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e000d1441a0fc4be7f01ddc25d5aa3b
https://doi.org/10.1177/009127009903901107
https://doi.org/10.1177/009127009903901107
Publikováno v:
Journal of Pharmacokinetics and Biopharmaceutics. 27:1-21
Prednisolone (Pred) and sirolimus (SIR) are immunosuppressive compounds acting through different mechanisms with moderate synergism found in vitro. Both drugs are metabolized partly by CYP3A enzymes. After iv administration of placebo, Pred (5 mg/kg)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::986f528ac98ed90b6eed1f51390dbb17
https://doi.org/10.1023/a:1020626611479
https://doi.org/10.1023/a:1020626611479
Publikováno v:
Transplantation. 65:1203-1209
The immunologic response is one barrier to successful transplantation and T cell-mediated rejection is the major contributor to acute and chronic rejections leading to graft failure (1). Thus, to avoid or delay rejection, inimunosuppressive therapy i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a61f0be731d58830694d8535c755657
https://doi.org/10.1097/00007890-199805150-00011
https://doi.org/10.1097/00007890-199805150-00011
Autor:
Geraldine M. Ferron, William J. Jusko
Publikováno v:
Pharmaceutical Research. 15:1888-1894
Purpose. To assess pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone (Pred, 1 mg/kg) and sirolimus (Sir, 0.25 mg/kg) in rabbits.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::350a7681a1e6fcefb7e22b5787826308
https://doi.org/10.1023/a:1011966308791
https://doi.org/10.1023/a:1011966308791